Talphera Inc. Cash Flow Conversion Efficiency
Talphera Inc. cash flow conversion efficiency. Based on the latest financial reports, Talphera Inc. (TLPH) has a cash flow conversion efficiency ratio of -0.272x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.92 Million) by net assets ($14.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Talphera Inc. (2008–2025)
Cash flow conversion efficiency of Talphera Inc. from 2008 to 2025. This chart illustrates how Talphera Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Talphera Inc. (TLPH) share price today for real-time trading data and today's change.
Talphera Inc. Cash Flow Conversion Ratio Explained
Talphera Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Talphera Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Talphera Inc. ranked by their cash flow conversion efficiency. Also see Talphera Inc. (TLPH) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vbt Yazilim AS
IS:VBTYZ
|
-0.057x |
|
Tu Liem Urban Development JSC
VN:NTL
|
-0.023x |
|
Here Group Limited
NASDAQ:HERE
|
0.227x |
|
Sambu Const
KO:001470
|
-0.064x |
|
WooriNet Inc
KQ:115440
|
0.037x |
|
Arlitech Electronic
TWO:6432
|
0.043x |
|
Sensus Healthcare Inc
NASDAQ:SRTS
|
0.048x |
|
ROK Resources Inc
V:ROK
|
0.003x |
Annual Cash Flow Conversion Efficiency for Talphera Inc. (2008–2025)
The table below shows the annual cash flow conversion efficiency of Talphera Inc. from 2008 to 2025. Review Talphera Inc. free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $17.04 Million | $-11.36 Million | -0.667x | +57.92% |
| 2024-12-31 | $8.00 Million | $-12.68 Million | -1.585x | -27.82% |
| 2023-12-31 | $14.11 Million | $-17.49 Million | -1.240x | +4.51% |
| 2022-12-31 | $21.81 Million | $-28.33 Million | -1.299x | -255.38% |
| 2021-12-31 | $-35.89 Million | $-30.00 Million | 0.836x | +21.02% |
| 2020-12-31 | $-55.75 Million | $-38.51 Million | 0.691x | -44.11% |
| 2019-12-31 | $-41.42 Million | $-51.18 Million | 1.236x | +118.08% |
| 2018-12-31 | $4.25 Million | $-29.07 Million | -6.836x | -938.53% |
| 2017-12-31 | $-36.51 Million | $-29.77 Million | 0.815x | -85.20% |
| 2016-12-31 | $-5.34 Million | $-29.39 Million | 5.508x | +1014.04% |
| 2015-12-31 | $33.11 Million | $-19.95 Million | -0.603x | +18.41% |
| 2014-12-31 | $46.66 Million | $-34.46 Million | -0.739x | -10994.20% |
| 2013-12-31 | $73.16 Million | $-487.00K | -0.007x | +99.08% |
| 2012-12-31 | $33.85 Million | $-24.58 Million | -0.726x | +17.01% |
| 2011-12-31 | $17.47 Million | $-15.29 Million | -0.875x | -571.70% |
| 2010-12-31 | $-65.89 Million | $-12.22 Million | 0.186x | -49.37% |
| 2009-12-31 | $-52.99 Million | $-19.42 Million | 0.366x | -35.38% |
| 2008-12-31 | $-33.34 Million | $-18.90 Million | 0.567x | -- |
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more